PET imaging for tyrosine kinase inhibitor (TKI) biodistribution in mice

Area of Science:

• Oncology
• Molecular Imaging
• Pharmacology

Background:

• Receptor tyrosine kinases (RTKs) are crucial in cancer cell growth and proliferation.
• Current tyrosine kinase inhibitors (TKIs) show limited efficacy in a subset of patients.
• Personalized medicine approaches are needed to improve cancer treatment outcomes.

Purpose of the Study:

• To describe a protocol for positron emission tomography (PET) imaging using radiolabeled TKIs.
• To evaluate the utility of PET imaging with TKIs in preclinical cancer models.
• To demonstrate the potential of this technique for patient stratification and drug development.

Main Methods:

• Development and validation of a PET imaging protocol using radiolabeled TKIs.
• Application of the protocol in preclinical cancer models.
• Quantitative analysis of imaging data to assess TKI distribution and target engagement.

Main Results:

• The described PET imaging protocol allows for accurate quantitative assessment of radiolabeled TKIs in vivo.
• PET imaging facilitates visualization of TKI biodistribution and target engagement in preclinical settings.
• The methodology shows potential for identifying patient populations likely to respond to TKI therapy.

Conclusions:

• PET imaging with radiolabeled TKIs is a valuable tool for preclinical cancer research.
• This approach can improve the accuracy of molecular imaging and aid in the development of targeted cancer therapies.
• PET-TKI imaging holds promise for enhancing patient stratification and optimizing TKI drug development pipelines.